Skip to content
This website uses cookies to help us understand the way visitors use our website. We can't identify you with them and we don't share the data with anyone else. If you click Reject we will set a single cookie to remember your preference. Find out more in our privacy policy.

National Products

We work with the NHS Accelerated Access Collaborative to accelerate the uptake of selected NICE-approved, cost-saving innovations into the NHS.

MedTech Funding Mandate (MTFM)

The NHS Long Term Plan committed to accelerate the uptake of selected innovative medical devices, diagnostics and digital products to patients faster, by developing the MedTech Funding Mandate policy. We work with NHS hospitals and commissioning organisations in the region to implement the existing innovations, to understand local and regional issues and to share learning from NHS organisations who have already implemented the innovations.

The technologies included in the MTFM 2022/23 policy are categorised into the following two themes:

  • Benign prostatic hyperplasia (BPH) is a common condition in ageing men and others with a prostate (trans women, some non-binary and some intersex people). It is currently treated with the surgical procedure, transurethral resection of the prostate (TURP) which usually requires the patient to stay in hospital for 1 to 3 days. Four less invasive innovations allow patients with BPH to be treated as day cases. Providers will not be expected to implement all four technologies, instead, each would be expected to work with its AHSN and the Getting It Right First Time (GIRFT) Urology Area Networks to understand its technology needs and the potential uptake locally.
  • Improving the patient experience during procedures technologies are innovative alternatives to otherwise more invasive and costly procedures. Thopaz and Spectra Optia use digital technology to increase efficiency and improve outcomes compared to current procedures and Xpress is a minimally invasive alternative to invasive sinus surgery, thus reducing the risk of complications and improving patient recovery, outcomes and experience.

To discuss the benefits of these products and understand how they can address your needs, contact the National Products team at

Rapid Uptake Products (RUP)

We support the RUP programme, which is designed to support stronger adoption and spread of innovations that have NICE approval. It identifies products that support the NHS Long Term Plan’s key clinical priorities, but have lower than expected uptake to date.

The 2021/22 programme builds on the successes of the previous cycle, with themes selected via an open, staged, selection process. This includes:

Lipid Management: High Intensity Statins, Ezetimibe and PCSK9 inhibitors

The Rapid Uptake Product (RUP) for lipid management is a novel clinical pathway. This innovation aims to improve a person’s lipid profile, by reducing cholesterol concentration in blood by treating patients with the right medicine for them. There are three treatment pathways available: high intensity statins (HIST), ezetimibe, and PCSK9 inhibitors (continued from 2019/20).

Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma: products NIOX VERO and NObreath

FeNO testing is a method that assists with the diagnosis of asthma by measuring fractional exhaled nitric oxide (FeNO) in the breath of patients suspected of having asthma. The aim of this innovation will be to improve patient care and outcomes by more effective diagnosis of patients suspected of having asthma.

Asthma Biologics for treating severe asthma: Reslizumab, Benralizumab, Mepolizumab and Omalizumab

Asthma Biologics can transform patient lives by reducing asthma attacks, asthma-related hospital admissions and long-term side effects of other treatments such as oral steroids. The aim of this innovation will be to improve patient care and outcomes by improving access to biologics for people with severe asthma. The programme focuses on optimising pathways that help with the early identification of people with uncontrolled asthma, appropriate referral of patients needing further specialist input and supporting patients to self-administer their asthma biologic at home.

To discuss the RUPs and how it can address your needs, please get in touch with the National Products team at